• Source: Bupropion/zonisamide

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity. Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor. The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.




See also


Naltrexone/bupropion




References

Kata Kunci Pencarian:

• Bupropion/zonisamide
• Zonisamide
• List of psychotropic medications
• Atomoxetine
• GABA analogue
• Conotoxin
• Stevens–Johnson syndrome
• JJC8-091
• Gabapentin
• Ketamine